Answers are grounded in this paper and cite their sources.
Experimental trial evaluates neuroprotective effects in locomotor dysfunction and memory impairment, suggesting therapeutic potential.
Neuroprotective potential of several 2-arylidene indanones 1a–d and 3a–c has been evaluated in animal models of locomotor dysfunction (MPTP-treated mice) and memory impairment (amyloid-β treated rats). Related behavioural parameters along with the biochemical estimation of the levels of several neurodegenerative markers like acetylcholinesterase, lipid peroxide, reactive oxygen, and nitric oxide species were studied. Further, histopathological and in silico studies were also carried out to gain the mechanistic insights. Treatment with indanones 1a–d and 3a–c demonstrated statistically significant improvement in locomotive and cognitive behaviour of the diseased animals along with the improved biochemical parameters. Docking and simulation studies revealed strong binding affinities of the compounds with various neuronal enzymes like MAO-B, AChE and β-secretase. Of all, the 4-propargyloxybenzylidene substituted indanone 3b displayed maximum potency in MPTP treated mice while 5-methoxyindanone analogues 1d ( para -methoxy) and 3c ( meta -propargyloxy) were found most active in Aβ 1-42 treated rats. The location of propargyloxy moiety on the 2-arylidene ring and the presence of 5-methoxy group on the indanone nucleus influenced the pharmacological responses of the compounds.
No takes yet. Share an insight, caveat, or question.
Chandra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: